We advice to follow risk factor guided mutation screening, since these schemes were shown to have a high c-statistic for detection of germline mutations and costs can be reduced up till 40% as compared to a screening in predefined order (SDHB > VHL > RET > SDHD) in each patient presenting with a catecholamine-secreting tumour. The gene discussed is SDHD; the disease is neoplasm.